Global Rheumatic Disorders Drugs Market Grow at (CAGR) of 4.46% to $80.04 billion in 2024

Global Rheumatic Disorders Drugs Market to 2024 research report covers key diseases of rheumatic disorders, market size, therapy area overview, etiology, Epidemiology Patterns and Forecasts - Prevalence and Patient Segmentation and key marketed products.

Pune, India - February 12, 2019 /MarketersMedia/ —

Global Rheumatic Disorders Drugs Market to 2024 - Increased Uptake of IL Inhibitors and JAK Inhibitors to Drive Growth as TNF Inhibitors Face Patent Expiry research report added to ReportsnReports online database.
The rheumatic disorder therapy area is multi-disciplinary in nature and encompasses conditions that affect joints, connective tissue, ligaments, tendons, cartilage, bone and muscle and which are characterized by chronic pain and a consequent reduction in function and motion. The majority of rheumatic disorders are treated using largely genericized pain management drugs, and there are no cures for any of the key indications, leaving a large unmet need for better disease-modifying drugs to be developed.

Get Discount on Rheumatic Disorders Drugs Market Research Report at https://www.reportsnreports.com/contacts/discount.aspx?name=1854866

This report covers all rheumatic disorders, but there is a particular focus on five key diseases, rheumatoid arthritis, osteoarthritis, osteoporosis, systemic lupus erythematosus and psoriatic arthritis, as these conditions have the largest pipelines within the therapy area.

The market size for rheumatic disorder therapeutics was $58.97 billion in 2017 and is expected to grow at a compound annual growth rate (CAGR) of 4.46% to $80.04 billion in 2024.

Scope

- How is the rheumatic disorders market landscape expected to change?
- Which drugs will face patent expiry, biosimilar competition and decreasing revenue over the forecast period?
- Overall, there are 1,069 products in the rheumatic disorder pipeline, how does the composition of the pipeline compare with that of the existing market?
- Which molecular targets are most prominent within the pipeline and how do the key indications differ in terms of their pipeline composition?
- The market size for rheumatic disorder therapeutics is expected to grow, from $58.97 billion in 2017 to $80.04 billion in 2024, at a CAGR of 4.46%. Which products will contribute to market growth most, and which will achieve blockbuster status?
- What types of companies are involved in the rheumatic disorder therapy area?
- Will the current market leaders retain their dominance over the forecast period?
- How many strategic consolidations have been completed in the past decade and which types of assets attract the largest deal values?

Reasons to Buy:
This report will allow you to -
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis for the five key indications
- Understand how the patent expiries of the key, blockbuster anti-TNF drugs will affect the Rheumatic Disorder Drug Market
- Identify trends and developments in the rheumatic disorder pipeline and consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates
- Identify which two drug classes will see particularly strong market growth over the forecast period
- See how or if the companies marketing anti-TNF drugs facing patent expiry will be able to offset biosimilar erosion
- Identify commercial opportunities in the rheumatic disorder deal landscape by analyzing trends in licensing and co-development deals

Direct Purchase of Rheumatic Disorders Drugs Market Research Report at https://www.reportsnreports.com/purchase.aspx?name=1854866

Table of Contents:
1. Introduction
2. Key Marketed Products
3. Pipeline Landscape Assessment
4. Multi-scenario Market Forecast to 2024
5. Company Analysis and Positioning
6. Strategic Consolidations
7. Appendix

Contact Info:
Name: Vishal Kalra
Email: Send Email
Organization: ReportsnReports
Website: https://www.reportsnreports.com/reports/1854866-global-rheumatic-disorders-drugs-market-to-2024-increased-uptake-of-il-inhibitors-and-jak-inhibitors-to-drive-growth-as-tnf-inhibitors-face-patent-expiry.html

Source URL: https://marketersmedia.com/global-rheumatic-disorders-drugs-market-grow-at-cagr-of-446-to-8004-billion-in-2024/481750

Source: MarketersMedia

Release ID: 481750

Latest News

In China, Apple's Cook says he's bullish on global economy

Mar 23, 2019

BEIJING — Apple CEO Tim Cook said Saturday that he is "extremely bullish" about the global economy based on the amount of innovation underway, and urged China to continue to "open up" amid complaints from the U.S. and others that it is shutting foreign firms out of key high-tech industries. In a speech at an economic forum in Beijing, Cook said Apple is less concerned with the short-term economic outlook because the tech giant makes investments looking ahead years or decades. "In the long term, I'm extremely bullish. I think the key to the economy, unlocking its potential has always...

Indonesian airline wants to cancel Boeing order after crash

Mar 23, 2019

JAKARTA, Indonesia — In a blow for Boeing, Indonesia's flag carrier is seeking the cancellation of a multibillion dollar order for 49 of the manufacturer's 737 Max 8 jets, citing a loss of confidence after two crashes within five months. It is the first announcement of a cancellation since Boeing's new model aircraft were grounded following fatal crashes in Indonesia and Ethiopia. PT Garuda Indonesia, which had ordered 50 Max 8 jets in 2014 and had received just one plane last year, sent a letter to Boeing last week requesting to cancel the order worth $4.9 billion, company spokesman Ikhsan...

Asian stocks stumble on doubts over US-China trade deal

Mar 23, 2019

SINGAPORE — Asian markets were mostly lower on Friday as caution set in ahead of U.S.-China trade talks in Beijing next week. The Shanghai Composite index gave up 0.8 percent to 3,077.56 and Hong Kong's Hang Seng lost 0.5 percent to 28,913.55. The Kospi in South Korea was flat at 2,184.94. Japan's Nikkei 225 index, reopening after a market holiday, dropped 0.2 percent to 21,453.10 after a report that inflation slowed slightly in February. The core consumer price index rose 0.7 percent from a year earlier, compared with January's 0.8 percent gain. A preliminary private survey, which was also released...

Thai exec guilty in poaching case, cleared of panther charge

Mar 23, 2019

BANGKOK — A Thai construction tycoon was convicted Tuesday on charges related to a high-profile poaching case last year but was found not guilty of possessing the carcass of an endangered black panther seen in photos that had sparked a public outcry. The Thong Pha Phum Provincial Court sentenced Premchai Karnasuta, the president of Italian-Thai Development PLC, to 16 months in prison for possessing the carcass of a protected Kalij pheasant, possessing firearms in public areas, and supporting others to hunt in a protected wildlife sanctuary. Premchai was arrested last February after park rangers found that he and three of...

Asia bracing for destruction by alien pest: fall armyworms

Mar 23, 2019

THA MUANG, Thailand — Fall armyworms, a longtime American pest, are munching their way around the globe, raising alarm now in Asia after entrenching themselves in Africa. Experts say the insect was first found outside the Americas in 2016, in Africa, where it has infested up to half of some crops of maize, sorghum and millet. It's now spread through Yemen and South Asia to Thailand and China. This new arrival to her territory worries Uraporn Nounart, a specialist on farm pests at Thailand's Agriculture Department. "We never had this one before. They just were found late last year and...

Sign up now!